Physician profile
Mark E Chen
NPI 1942838826
$2,560.82
in general payments reported to CMS, 2019-2025
29 companies · $1,421 in 2025
The $1,421 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.77 · 2022: $112 · 2023: $278 · 2024: $734 · 2025: $1,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,276.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $285.24 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Gilead Sciences, INC. | $238.04 | 2024-2025 | Livdelzi |
| Smith+Nephew, INC. | $237.57 | 2024-2025 | Collagenase Santyl, Regranex |
| Pfizer INC. | $179.06 | 2023-2024 | |
| Lifenet Health | $177.08 | 2025 | Theragenesis Wound Matrix |
| Mimedx Group, INC. | $172.49 | 2025 | |
| Corcept Therapeutics | $156.19 | 2024 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $119.84 | 2024-2025 | |
| Dexcom, INC. | $113.91 | 2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $107.77 | 2022-2025 | |
| Novo Nordisk INC | $103.13 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Ascensia Diabetes Care US INC. | $74.64 | 2025 | |
| Janssen Pharmaceuticals, INC | $74.38 | 2024-2025 | Spravato |
| Radius Health, INC. | $37.87 | 2025 | Tymlos |
| Astrazeneca Pharmaceuticals Lp | $30.98 | 2024-2025 | Farxiga |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $30.76 | 2025 | |
| Grifols USA, LLC | $28.49 | 2023 | Prolastin-C Liquid |
| Solventum Corporation | $28.13 | 2024 | Activ.A.C. |
| Amgen INC. | $24.92 | 2025 | Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.92 | 2024 | Caplyta |
| Xeris Pharmaceuticals, INC. | $21.28 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.92 | 2024 | |
| Evofem Biosciences, INC. | $19.38 | 2022 | |
| Lilly USA, LLC | $17.56 | 2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.81 | 2025 | Jardiance |
| Exact Sciences Corporation | $15.64 | 2023 | Cologuard Collection Kit |
| Azurity Pharmaceuticals, INC. | $13.92 | 2025 | Edarbyclor |
| Kowa Pharmaceuticals America, INC. | $13.50 | 2024 | Zoryve |
| Mayne Pharma Commercial LLC | $6.19 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.